Abstract

e17091Background: TOPK (T-lymphokine-activated killer cell-originated protein kinase) status in ovarian cancer is not well known. We aimed to clarify the clinical significance of TOPK expression in...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Data from T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer
Yusuke Nakamura ... Jae-Hyun Park
-
Yusuke Nakamura, et. al.Yusuke Nakamura ... Jae-Hyun Park
31 Mar 2023
T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.
Yuji Ikeda ... Shuhei Okabe
Clinical cancer research : an official journal of the American Association for Cancer Research | VOL. 22
Yuji Ikeda, et. al.Yuji Ikeda ... Shuhei Okabe
15 Dec 2016
Data from T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer
Akiko Iwasa ... Yusuke Nakamura
-
Akiko Iwasa, et. al.Akiko Iwasa ... Yusuke Nakamura
31 Mar 2023
T-lymphokine-activated killer cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in glioma.
Chuntao Quan ... Meng Yan
Oncotarget | VOL. 9
Chuntao Quan, et. al.Chuntao Quan ... Meng Yan
26 Dec 2017
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
Steven J Katz ... Allison W Kurian
Journal of Clinical Oncology | VOL. -
Steven J Katz, et. al.Steven J Katz ... Allison W Kurian
15 Jul 2024
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
Yoon-Koo Kang ... Sung Hoon Noh
Journal of Clinical Oncology | VOL. -
Yoon-Koo Kang, et. al.Yoon-Koo Kang ... Sung Hoon Noh
12 Jul 2024
Individualized Local Recurrence Estimates for Ductal Carcinoma In Situ.
Laura E G Warren ... Jennifer R Bellon
Journal of Clinical Oncology | VOL. -
Laura E G Warren, et. al.Laura E G Warren ... Jennifer R Bellon
11 Jul 2024
Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?
Aoba Okeya ... Chikako Shimizu
Journal of Clinical Oncology | VOL. -
Aoba Okeya, et. al.Aoba Okeya ... Chikako Shimizu
11 Jul 2024
View more papers